In this study, we showed that MSI-1436 reduced ex-vivo liver inflammation and fibrosis by activating antifibrotic factors including TIMP-1 and thus might be considered as a future molecule for the treatment of liver-related inflammation and fibrosis in equine metabolic syndrome affected horses. The gene discussed is TIMP1; the disease is Hepatitis.